AbbVie (NYSE:ABBV) Shares Up 1.9% - Should You Buy?

Key Points

• Pipeline boost: Late‑breaking Phase 2 data for Elahere (mirvetuximab) showed encouraging efficacy/safety and AbbVie struck an exclusive global licensing deal with Haisco (terms reported ~ $715–$745M), strengthening its oncology and pain growth prospects.
• Analyst bullishness: Multiple firms raised price targets (Guggenheim to $249, RBC $260, Piper Sandler $299) and the consensus is a "Moderate Buy" with a $253 average target, supporting investor confidence.
• Financials & dividend: AbbVie beat Q earnings (EPS $2.71 vs $2.65; revenue $16.62B, +10% YoY), set FY2026 guidance of $14.370–$14.570 EPS, and announced a $1.73 quarterly dividend (3.3% yield).

AbbVie Inc. (NYSE:ABBV - Get Free Report)'s stock price shot up 1.9% during mid-day trading on Tuesday . The stock traded as high as $210.42 and last traded at $210.29. 6,196,803 shares traded hands during trading, a decline of 14% from the average session volume of 7,187,451 shares. The stock had previously closed at $206.47.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Late‑breaking Phase 2 data for Elahere (mirvetuximab) in platinum‑sensitive ovarian cancer showed encouraging efficacy and safety in an underserved population — news that boosts AbbVie's oncology story and potential revenue upside if the asset advances. AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story
• Positive Sentiment: AbbVie struck an exclusive global licensing deal with China’s Haisco (terms reported up to ~$715–$745M) to develop novel pain medicines outside mainland China, Hong Kong and Macau — a move that expands AbbVie's pain pipeline and diversifies its late‑stage portfolio. AbbVie inks $715m deal with Chinese biotech Haisco for two acute pain assets
• Positive Sentiment: An analyst price target was raised to $249, providing a bullish valuation anchor that can support investor confidence and buying interest. AbbVie NYSE: ABBV Price Target Raised to $249.00
• Neutral Sentiment: AbbVie's ABBV‑438 myeloma Phase 1 trial update was posted — an early‑stage, first‑in‑human study that represents optionality for long‑term oncology growth but is too preliminary to move near‑term revenue forecasts. AbbVie’s ABBV-438 Myeloma Trial: Early-Stage Bet on Long-Term Oncology Growth
• Neutral Sentiment: Analysts note that neuroscience products (Botox, Vraylar) could drive stronger top‑line performance in Q1, supporting near‑term revenue stability as legacy drugs face pressures. This is supportive but largely anticipated. Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?
• Neutral Sentiment: Marketing/branding activity for Allergan Aesthetics (Natrelle) — e.g., a public influencer story — raises consumer visibility but is unlikely to materially affect the broader drug revenue runway. Erin Lichy Gets Real About Her Natrelle® Breast Augmentation
• Negative Sentiment: On weight‑loss competition, coverage notes AbbVie is progressing but remains well behind market leader Eli Lilly — a reminder AbbVie faces steep competition and execution risk in fast‑growing obesity therapeutics. That competitive gap could cap upside if investors were expecting a rapid challenge to leaders. Could AbbVie Crash Lilly's Weight‑Loss Party?

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ABBV. Guggenheim lifted their price target on AbbVie from $242.00 to $249.00 and gave the stock a "buy" rating in a research note on Friday. William Blair reaffirmed an "outperform" rating on shares of AbbVie in a research note on Monday, March 9th. Wall Street Zen downgraded AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Royal Bank Of Canada began coverage on AbbVie in a research note on Tuesday, February 24th. They set an "outperform" rating and a $260.00 price target for the company. Finally, Piper Sandler lifted their price target on AbbVie from $289.00 to $299.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $253.00.

AbbVie Trading Up 1.9%

The firm's 50 day moving average is $219.96 and its two-hundred day moving average is $223.96. The stock has a market cap of $371.83 billion, a price-to-earnings ratio of 89.11, a P/E/G ratio of 0.75 and a beta of 0.38.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the previous year, the company posted $2.16 EPS. The firm's revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie's payout ratio is presently 293.22%.

Insider Transactions at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company's stock, valued at $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.06% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Brighton Jones LLC grew its holdings in shares of AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock worth $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC grew its holdings in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock worth $1,294,000 after purchasing an additional 3,064 shares during the period. Schnieders Capital Management LLC. grew its holdings in shares of AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company's stock worth $3,056,000 after purchasing an additional 789 shares during the period. Ieq Capital LLC grew its holdings in shares of AbbVie by 4.6% during the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company's stock worth $22,281,000 after purchasing an additional 5,274 shares during the period. Finally, Worldquant Millennium Advisors LLC grew its holdings in shares of AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company's stock worth $210,685,000 after purchasing an additional 612,702 shares during the period. Institutional investors and hedge funds own 70.23% of the company's stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.